IDEAYA Biosciences, Inc.
Get $10 bonus on your first $100 deposit for IDYA
Get $10 bonus on your first $100 deposit for IDYA
IDEAYA Biosciences, Inc. (IDYA) Stock Competitors & Peer Comparison
See (IDYA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IDYA | $31.61 | +3.64% | 2.9B | -25.64 | -$1.28 | N/A |
| VRTX | $440.89 | +1.06% | 111.8B | 28.74 | $15.31 | N/A |
| REGN | $754.38 | +0.74% | 77.6B | 17.99 | $41.49 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $831.67 | +4.00% | 50.1B | 41.39 | $19.55 | N/A |
| ALNY | $342.61 | +6.36% | 44.2B | 141.70 | $2.35 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $151.88 | -1.89% | 32.6B | -23.54 | -$6.42 | N/A |
| RVMD | $143.45 | +48.76% | 27B | -22.91 | -$5.95 | N/A |
| UTHR | $580.03 | +1.45% | 25.3B | 20.75 | $27.84 | N/A |
Stock Comparison
IDYA vs VRTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VRTX has a market cap of 111.8B. Regarding current trading prices, IDYA is priced at $31.61, while VRTX trades at $440.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas VRTX's P/E ratio is 28.74. In terms of profitability, IDYA's ROE is -0.11%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IDYA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRTX's competition here
IDYA vs REGN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, REGN has a market cap of 77.6B. Regarding current trading prices, IDYA is priced at $31.61, while REGN trades at $754.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas REGN's P/E ratio is 17.99. In terms of profitability, IDYA's ROE is -0.11%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IDYA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check REGN's competition here
IDYA vs VRNA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IDYA is priced at $31.61, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IDYA's ROE is -0.11%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, IDYA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRNA's competition here
IDYA vs ARGX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ARGX has a market cap of 50.1B. Regarding current trading prices, IDYA is priced at $31.61, while ARGX trades at $831.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ARGX's P/E ratio is 41.39. In terms of profitability, IDYA's ROE is -0.11%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, IDYA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ARGX's competition here
IDYA vs ALNY Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ALNY has a market cap of 44.2B. Regarding current trading prices, IDYA is priced at $31.61, while ALNY trades at $342.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ALNY's P/E ratio is 141.70. In terms of profitability, IDYA's ROE is -0.11%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, IDYA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALNY's competition here
IDYA vs SGEN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IDYA is priced at $31.61, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IDYA's ROE is -0.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IDYA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SGEN's competition here
IDYA vs INSM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, INSM has a market cap of 32.6B. Regarding current trading prices, IDYA is priced at $31.61, while INSM trades at $151.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas INSM's P/E ratio is -23.54. In terms of profitability, IDYA's ROE is -0.11%, compared to INSM's ROE of -1.68%. Regarding short-term risk, IDYA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check INSM's competition here
IDYA vs RVMD Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RVMD has a market cap of 27B. Regarding current trading prices, IDYA is priced at $31.61, while RVMD trades at $143.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RVMD's P/E ratio is -22.91. In terms of profitability, IDYA's ROE is -0.11%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, IDYA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RVMD's competition here
IDYA vs UTHR Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, UTHR has a market cap of 25.3B. Regarding current trading prices, IDYA is priced at $31.61, while UTHR trades at $580.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas UTHR's P/E ratio is 20.75. In terms of profitability, IDYA's ROE is -0.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IDYA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check UTHR's competition here
IDYA vs BNTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, IDYA is priced at $31.61, while BNTX trades at $99.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BNTX's P/E ratio is -17.84. In terms of profitability, IDYA's ROE is -0.11%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, IDYA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BNTX's competition here
IDYA vs RPRX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RPRX has a market cap of 20.7B. Regarding current trading prices, IDYA is priced at $31.61, while RPRX trades at $48.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RPRX's P/E ratio is 27.21. In terms of profitability, IDYA's ROE is -0.11%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, IDYA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RPRX's competition here
IDYA vs ROIV Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ROIV has a market cap of 20.7B. Regarding current trading prices, IDYA is priced at $31.61, while ROIV trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ROIV's P/E ratio is -24.74. In terms of profitability, IDYA's ROE is -0.11%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IDYA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ROIV's competition here
IDYA vs BGNE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IDYA is priced at $31.61, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IDYA's ROE is -0.11%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, IDYA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BGNE's competition here
IDYA vs MRNA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MRNA has a market cap of 20B. Regarding current trading prices, IDYA is priced at $31.61, while MRNA trades at $52.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas MRNA's P/E ratio is -6.98. In terms of profitability, IDYA's ROE is -0.11%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, IDYA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRNA's competition here
IDYA vs INCY Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, INCY has a market cap of 19B. Regarding current trading prices, IDYA is priced at $31.61, while INCY trades at $97.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas INCY's P/E ratio is 14.91. In terms of profitability, IDYA's ROE is -0.11%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IDYA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check INCY's competition here
IDYA vs DNA-WT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IDYA is priced at $31.61, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, IDYA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check DNA-WT's competition here
IDYA vs GMAB Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, GMAB has a market cap of 17.4B. Regarding current trading prices, IDYA is priced at $31.61, while GMAB trades at $29.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas GMAB's P/E ratio is 18.31. In terms of profitability, IDYA's ROE is -0.11%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IDYA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check GMAB's competition here
IDYA vs ASND Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ASND has a market cap of 15.3B. Regarding current trading prices, IDYA is priced at $31.61, while ASND trades at $246.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ASND's P/E ratio is -57.27. In terms of profitability, IDYA's ROE is -0.11%, compared to ASND's ROE of +1.28%. Regarding short-term risk, IDYA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ASND's competition here
IDYA vs BBIO Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BBIO has a market cap of 15.1B. Regarding current trading prices, IDYA is priced at $31.61, while BBIO trades at $79.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BBIO's P/E ratio is -20.60. In terms of profitability, IDYA's ROE is -0.11%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, IDYA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BBIO's competition here
IDYA vs SMMT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SMMT has a market cap of 14.9B. Regarding current trading prices, IDYA is priced at $31.61, while SMMT trades at $20.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas SMMT's P/E ratio is -13.91. In terms of profitability, IDYA's ROE is -0.11%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, IDYA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SMMT's competition here
IDYA vs KRTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IDYA is priced at $31.61, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IDYA's ROE is -0.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IDYA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KRTX's competition here
IDYA vs IONS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, IDYA is priced at $31.61, while IONS trades at $76.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas IONS's P/E ratio is -31.49. In terms of profitability, IDYA's ROE is -0.11%, compared to IONS's ROE of -0.69%. Regarding short-term risk, IDYA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IONS's competition here
IDYA vs MDGL Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, IDYA is priced at $31.61, while MDGL trades at $533.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas MDGL's P/E ratio is -40.91. In terms of profitability, IDYA's ROE is -0.11%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, IDYA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MDGL's competition here
IDYA vs EXEL Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, IDYA is priced at $31.61, while EXEL trades at $45.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas EXEL's P/E ratio is 16.17. In terms of profitability, IDYA's ROE is -0.11%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, IDYA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check EXEL's competition here
IDYA vs JAZZ Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, JAZZ has a market cap of 12B. Regarding current trading prices, IDYA is priced at $31.61, while JAZZ trades at $198.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas JAZZ's P/E ratio is -33.44. In terms of profitability, IDYA's ROE is -0.11%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, IDYA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check JAZZ's competition here
IDYA vs RNAM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IDYA is priced at $31.61, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IDYA's ROE is -0.11%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IDYA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RNAM's competition here
IDYA vs BMRN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, IDYA is priced at $31.61, while BMRN trades at $55.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BMRN's P/E ratio is 30.49. In terms of profitability, IDYA's ROE is -0.11%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, IDYA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BMRN's competition here
IDYA vs RXDX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IDYA is priced at $31.61, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IDYA's ROE is -0.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RXDX's competition here
IDYA vs AXSM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, AXSM has a market cap of 9.1B. Regarding current trading prices, IDYA is priced at $31.61, while AXSM trades at $183.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas AXSM's P/E ratio is -48.33. In terms of profitability, IDYA's ROE is -0.11%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, IDYA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AXSM's competition here
IDYA vs TECH Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TECH has a market cap of 9B. Regarding current trading prices, IDYA is priced at $31.61, while TECH trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas TECH's P/E ratio is 108.55. In terms of profitability, IDYA's ROE is -0.11%, compared to TECH's ROE of +0.04%. Regarding short-term risk, IDYA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TECH's competition here
IDYA vs ARWR Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ARWR has a market cap of 8.9B. Regarding current trading prices, IDYA is priced at $31.61, while ARWR trades at $66.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ARWR's P/E ratio is 39.87. In terms of profitability, IDYA's ROE is -0.11%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, IDYA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ARWR's competition here
IDYA vs PCVX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, IDYA is priced at $31.61, while PCVX trades at $62.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas PCVX's P/E ratio is -10.97. In terms of profitability, IDYA's ROE is -0.11%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, IDYA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PCVX's competition here
IDYA vs IMGN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IDYA is priced at $31.61, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IDYA's ROE is -0.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IDYA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IMGN's competition here
IDYA vs BPMC Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IDYA is priced at $31.61, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IDYA's ROE is -0.11%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IDYA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BPMC's competition here
IDYA vs CYTK Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $31.61, while CYTK trades at $67.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CYTK's P/E ratio is -10.20. In terms of profitability, IDYA's ROE is -0.11%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, IDYA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CYTK's competition here
IDYA vs CERE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $31.61, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CERE's P/E ratio is -16.47. In terms of profitability, IDYA's ROE is -0.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IDYA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CERE's competition here
IDYA vs ABVX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, IDYA is priced at $31.61, while ABVX trades at $124.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ABVX's P/E ratio is -21.55. In terms of profitability, IDYA's ROE is -0.11%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, IDYA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ABVX's competition here
IDYA vs HALO Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, IDYA is priced at $31.61, while HALO trades at $68.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas HALO's P/E ratio is 26.16. In terms of profitability, IDYA's ROE is -0.11%, compared to HALO's ROE of +0.93%. Regarding short-term risk, IDYA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check HALO's competition here
IDYA vs KRYS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KRYS has a market cap of 7.8B. Regarding current trading prices, IDYA is priced at $31.61, while KRYS trades at $274.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas KRYS's P/E ratio is 39.10. In terms of profitability, IDYA's ROE is -0.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IDYA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KRYS's competition here
IDYA vs NUVL Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, NUVL has a market cap of 7.6B. Regarding current trading prices, IDYA is priced at $31.61, while NUVL trades at $106.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas NUVL's P/E ratio is -17.79. In terms of profitability, IDYA's ROE is -0.11%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, IDYA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check NUVL's competition here
IDYA vs IBRX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, IDYA is priced at $31.61, while IBRX trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas IBRX's P/E ratio is -19.21. In terms of profitability, IDYA's ROE is -0.11%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, IDYA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IBRX's competition here
IDYA vs MTSR Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IDYA is priced at $31.61, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IDYA's ROE is -0.11%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IDYA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MTSR's competition here
IDYA vs KYMR Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KYMR has a market cap of 7.2B. Regarding current trading prices, IDYA is priced at $31.61, while KYMR trades at $89.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas KYMR's P/E ratio is -23.99. In terms of profitability, IDYA's ROE is -0.11%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, IDYA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KYMR's competition here
IDYA vs MRUS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IDYA is priced at $31.61, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IDYA's ROE is -0.11%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IDYA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRUS's competition here
IDYA vs BLTE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, IDYA is priced at $31.61, while BLTE trades at $174.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BLTE's P/E ratio is -74.97. In terms of profitability, IDYA's ROE is -0.11%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, IDYA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BLTE's competition here
IDYA vs ACLX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IDYA is priced at $31.61, while ACLX trades at $114.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ACLX's P/E ratio is -28.15. In terms of profitability, IDYA's ROE is -0.11%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IDYA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ACLX's competition here
IDYA vs PRAX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, IDYA is priced at $31.61, while PRAX trades at $340.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas PRAX's P/E ratio is -23.52. In terms of profitability, IDYA's ROE is -0.11%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, IDYA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PRAX's competition here
IDYA vs RETA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $31.61, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RETA's P/E ratio is -66.29. In terms of profitability, IDYA's ROE is -0.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IDYA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RETA's competition here
IDYA vs PTGX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PTGX has a market cap of 6.2B. Regarding current trading prices, IDYA is priced at $31.61, while PTGX trades at $103.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas PTGX's P/E ratio is -47.60. In terms of profitability, IDYA's ROE is -0.11%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, IDYA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PTGX's competition here
IDYA vs RYTM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, IDYA is priced at $31.61, while RYTM trades at $88.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RYTM's P/E ratio is -27.91. In terms of profitability, IDYA's ROE is -0.11%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, IDYA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RYTM's competition here
IDYA vs COGT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, IDYA is priced at $31.61, while COGT trades at $37.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas COGT's P/E ratio is -16.91. In terms of profitability, IDYA's ROE is -0.11%, compared to COGT's ROE of -1.00%. Regarding short-term risk, IDYA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check COGT's competition here
IDYA vs CNTA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, IDYA is priced at $31.61, while CNTA trades at $39.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CNTA's P/E ratio is -27.10. In terms of profitability, IDYA's ROE is -0.11%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, IDYA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CNTA's competition here
IDYA vs PTCT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, IDYA is priced at $31.61, while PTCT trades at $73.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas PTCT's P/E ratio is 8.21. In terms of profitability, IDYA's ROE is -0.11%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, IDYA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check PTCT's competition here
IDYA vs CELC Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CELC has a market cap of 5.8B. Regarding current trading prices, IDYA is priced at $31.61, while CELC trades at $120.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CELC's P/E ratio is -31.68. In terms of profitability, IDYA's ROE is -0.11%, compared to CELC's ROE of -2.03%. Regarding short-term risk, IDYA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CELC's competition here
IDYA vs CGON Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, IDYA is priced at $31.61, while CGON trades at $69.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CGON's P/E ratio is -32.55. In terms of profitability, IDYA's ROE is -0.11%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IDYA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CGON's competition here
IDYA vs SRRK Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, IDYA is priced at $31.61, while SRRK trades at $50.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas SRRK's P/E ratio is -15.05. In terms of profitability, IDYA's ROE is -0.11%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, IDYA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SRRK's competition here
IDYA vs ALKS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, IDYA is priced at $31.61, while ALKS trades at $34.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ALKS's P/E ratio is 23.60. In terms of profitability, IDYA's ROE is -0.11%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, IDYA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALKS's competition here
IDYA vs CDTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IDYA is priced at $31.61, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IDYA's ROE is -0.11%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IDYA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CDTX's competition here
IDYA vs ABCM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $31.61, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IDYA's ROE is -0.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IDYA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ABCM's competition here
IDYA vs ISEE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $31.61, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IDYA's ROE is -0.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IDYA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ISEE's competition here
IDYA vs CAI Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, IDYA is priced at $31.61, while CAI trades at $20.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CAI's P/E ratio is -6.03. In terms of profitability, IDYA's ROE is -0.11%, compared to CAI's ROE of +0.25%. Regarding short-term risk, IDYA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CAI's competition here
IDYA vs TGTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, IDYA is priced at $31.61, while TGTX trades at $34.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas TGTX's P/E ratio is 12.20. In terms of profitability, IDYA's ROE is -0.11%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, IDYA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TGTX's competition here
IDYA vs CRSP Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, IDYA is priced at $31.61, while CRSP trades at $57.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CRSP's P/E ratio is -8.47. In terms of profitability, IDYA's ROE is -0.11%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, IDYA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CRSP's competition here
IDYA vs APLS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, IDYA is priced at $31.61, while APLS trades at $40.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas APLS's P/E ratio is 226.89. In terms of profitability, IDYA's ROE is -0.11%, compared to APLS's ROE of +0.08%. Regarding short-term risk, IDYA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check APLS's competition here
IDYA vs FBIOX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, IDYA is priced at $31.61, while FBIOX trades at $25.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.11%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IDYA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FBIOX's competition here
IDYA vs IMVT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, IDYA is priced at $31.61, while IMVT trades at $25.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas IMVT's P/E ratio is -9.41. In terms of profitability, IDYA's ROE is -0.11%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IDYA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IMVT's competition here
IDYA vs ERAS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, IDYA is priced at $31.61, while ERAS trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ERAS's P/E ratio is -37.07. In terms of profitability, IDYA's ROE is -0.11%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, IDYA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ERAS's competition here
IDYA vs APGE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, IDYA is priced at $31.61, while APGE trades at $88.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas APGE's P/E ratio is -20.55. In terms of profitability, IDYA's ROE is -0.11%, compared to APGE's ROE of -0.37%. Regarding short-term risk, IDYA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check APGE's competition here
IDYA vs MIRM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, IDYA is priced at $31.61, while MIRM trades at $98.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas MIRM's P/E ratio is -205.30. In terms of profitability, IDYA's ROE is -0.11%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, IDYA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MIRM's competition here
IDYA vs TERN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, IDYA is priced at $31.61, while TERN trades at $52.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas TERN's P/E ratio is -51.08. In terms of profitability, IDYA's ROE is -0.11%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IDYA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TERN's competition here
IDYA vs XENE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, IDYA is priced at $31.61, while XENE trades at $59.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas XENE's P/E ratio is -13.20. In terms of profitability, IDYA's ROE is -0.11%, compared to XENE's ROE of -0.56%. Regarding short-term risk, IDYA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check XENE's competition here
IDYA vs CORT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CORT has a market cap of 4.6B. Regarding current trading prices, IDYA is priced at $31.61, while CORT trades at $44.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CORT's P/E ratio is 52.80. In terms of profitability, IDYA's ROE is -0.11%, compared to CORT's ROE of +0.15%. Regarding short-term risk, IDYA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CORT's competition here
IDYA vs FOLD Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.61, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas FOLD's P/E ratio is -160.67. In terms of profitability, IDYA's ROE is -0.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IDYA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FOLD's competition here
IDYA vs AKRO Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.61, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IDYA's ROE is -0.11%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AKRO's competition here
IDYA vs ALPN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $31.61, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IDYA's ROE is -0.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IDYA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALPN's competition here
IDYA vs LGND Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, LGND has a market cap of 4.3B. Regarding current trading prices, IDYA is priced at $31.61, while LGND trades at $230.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas LGND's P/E ratio is 34.82. In terms of profitability, IDYA's ROE is -0.11%, compared to LGND's ROE of +0.14%. Regarding short-term risk, IDYA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check LGND's competition here
IDYA vs OPT Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $31.61, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas OPT's P/E ratio is -1.52. In terms of profitability, IDYA's ROE is -0.11%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IDYA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check OPT's competition here
IDYA vs NAMS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, NAMS has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $31.61, while NAMS trades at $36.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas NAMS's P/E ratio is -21.08. In terms of profitability, IDYA's ROE is -0.11%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, IDYA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check NAMS's competition here
IDYA vs MRTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $31.61, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IDYA's ROE is -0.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IDYA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRTX's competition here
IDYA vs CRNX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, IDYA is priced at $31.61, while CRNX trades at $40.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CRNX's P/E ratio is -7.87. In terms of profitability, IDYA's ROE is -0.11%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, IDYA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CRNX's competition here
IDYA vs VKTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, IDYA is priced at $31.61, while VKTX trades at $36.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas VKTX's P/E ratio is -10.97. In terms of profitability, IDYA's ROE is -0.11%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, IDYA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VKTX's competition here
IDYA vs SYRE Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SYRE has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.61, while SYRE trades at $63.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas SYRE's P/E ratio is -31.95. In terms of profitability, IDYA's ROE is -0.11%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, IDYA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check SYRE's competition here
IDYA vs TLX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.61, while TLX trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas TLX's P/E ratio is -562.00. In terms of profitability, IDYA's ROE is -0.11%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IDYA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TLX's competition here
IDYA vs RYZB Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $31.61, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IDYA's ROE is -0.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IDYA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RYZB's competition here
IDYA vs CBAY Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $31.61, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IDYA's ROE is -0.11%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IDYA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CBAY's competition here
IDYA vs ACAD Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $31.61, while ACAD trades at $21.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas ACAD's P/E ratio is 9.33. In terms of profitability, IDYA's ROE is -0.11%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, IDYA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ACAD's competition here
IDYA vs EWTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, IDYA is priced at $31.61, while EWTX trades at $34.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas EWTX's P/E ratio is -20.76. In terms of profitability, IDYA's ROE is -0.11%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, IDYA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check EWTX's competition here
IDYA vs SWTX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IDYA is priced at $31.61, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IDYA's ROE is -0.11%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, IDYA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SWTX's competition here
IDYA vs KNSA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, IDYA is priced at $31.61, while KNSA trades at $45.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas KNSA's P/E ratio is 63.07. In terms of profitability, IDYA's ROE is -0.11%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, IDYA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KNSA's competition here
IDYA vs DNTH Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, IDYA is priced at $31.61, while DNTH trades at $95.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas DNTH's P/E ratio is -21.42. In terms of profitability, IDYA's ROE is -0.11%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, IDYA is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check DNTH's competition here
IDYA vs LQDA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, LQDA has a market cap of 3.4B. Regarding current trading prices, IDYA is priced at $31.61, while LQDA trades at $38.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas LQDA's P/E ratio is -48.56. In terms of profitability, IDYA's ROE is -0.11%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, IDYA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check LQDA's competition here
IDYA vs LEGN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, IDYA is priced at $31.61, while LEGN trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas LEGN's P/E ratio is -10.92. In terms of profitability, IDYA's ROE is -0.11%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, IDYA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check LEGN's competition here
IDYA vs DYN Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while DYN trades at $19.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas DYN's P/E ratio is -5.48. In terms of profitability, IDYA's ROE is -0.11%, compared to DYN's ROE of -0.61%. Regarding short-term risk, IDYA is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check DYN's competition here
IDYA vs GPCR Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while GPCR trades at $55.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas GPCR's P/E ratio is -22.60. In terms of profitability, IDYA's ROE is -0.11%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, IDYA is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check GPCR's competition here
IDYA vs VERA Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, VERA has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while VERA trades at $45.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas VERA's P/E ratio is -9.38. In terms of profitability, IDYA's ROE is -0.11%, compared to VERA's ROE of -0.60%. Regarding short-term risk, IDYA is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VERA's competition here
IDYA vs CPRX Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while CPRX trades at $26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas CPRX's P/E ratio is 15.08. In terms of profitability, IDYA's ROE is -0.11%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IDYA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CPRX's competition here
IDYA vs TARS Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, TARS has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while TARS trades at $72.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas TARS's P/E ratio is -45.69. In terms of profitability, IDYA's ROE is -0.11%, compared to TARS's ROE of -0.20%. Regarding short-term risk, IDYA is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TARS's competition here
IDYA vs DNLI Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while DNLI trades at $20.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas DNLI's P/E ratio is -6.54. In terms of profitability, IDYA's ROE is -0.11%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, IDYA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check DNLI's competition here
IDYA vs BEAM Comparison April 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 2.9B. In comparison, BEAM has a market cap of 3.1B. Regarding current trading prices, IDYA is priced at $31.61, while BEAM trades at $31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -25.64, whereas BEAM's P/E ratio is -37.26. In terms of profitability, IDYA's ROE is -0.11%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, IDYA is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BEAM's competition here